MDT

96.91

-0.67%↓

A

147.87

-0.47%↓

VEEV

232.45

-3%↓

HQY

84.34

-10.55%↓

PHR.US

17.13

-0.23%↓

MDT

96.91

-0.67%↓

A

147.87

-0.47%↓

VEEV

232.45

-3%↓

HQY

84.34

-10.55%↓

PHR.US

17.13

-0.23%↓

MDT

96.91

-0.67%↓

A

147.87

-0.47%↓

VEEV

232.45

-3%↓

HQY

84.34

-10.55%↓

PHR.US

17.13

-0.23%↓

MDT

96.91

-0.67%↓

A

147.87

-0.47%↓

VEEV

232.45

-3%↓

HQY

84.34

-10.55%↓

PHR.US

17.13

-0.23%↓

MDT

96.91

-0.67%↓

A

147.87

-0.47%↓

VEEV

232.45

-3%↓

HQY

84.34

-10.55%↓

PHR.US

17.13

-0.23%↓

Search

PerkinElmer Inc

Gesloten

SectorGezondheidszorg

0

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

Max

Belangrijke statistieken

By Trading Economics

Inkomsten

-8.6M

47M

Verkoop

-21M

699M

K/W

Sectorgemiddelde

52.608

87.826

EPS

0.4

Dividendrendement

0.29

Winstmarge

6.675

Werknemers

11,000

EBITDA

-14M

181M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+11.47% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

0.29%

2.26%

Volgende Winsten

30 jan 2026

Volgende dividenddatum

6 feb 2026

Volgende Ex Dividend datum

16 jan 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

569M

12B

Vorige openingsprijs

0

Vorige sluitingsprijs

0

Nieuwssentiment

By Acuity

29%

71%

87 / 370 Rangschikking in Healthcare

PerkinElmer Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

12 jan 2026, 23:54 UTC

Marktinformatie

CBA Could Underperform Again in 2026 -- Market Talk

12 jan 2026, 23:48 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

12 jan 2026, 23:48 UTC

Marktinformatie

Nikkei May Rise on Weaker Yen -- Market Talk

12 jan 2026, 23:43 UTC

Marktinformatie

Gold Edges Lower on Likely Technical Correction -- Market Talk

12 jan 2026, 23:18 UTC

Acquisities, Fusies, Overnames

Paramount Sues Warner Bros., Plans Proxy Fight. The Ellisons Aren't Giving Up. -- Barrons.com

12 jan 2026, 21:56 UTC

Marktinformatie

Light & Wonder Gets Positive Outcome From Lawsuit -- Market Talk

12 jan 2026, 21:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

12 jan 2026, 21:50 UTC

Marktinformatie

Health Care Roundup: Market Talk

12 jan 2026, 21:50 UTC

Marktinformatie
Winsten

Auto & Transport Roundup: Market Talk

12 jan 2026, 21:18 UTC

Marktinformatie

Global Equities Roundup: Market Talk

12 jan 2026, 21:18 UTC

Marktinformatie

Pfizer CEO Sees Large Cash Market for Obesity Drugs -- Market Talk

12 jan 2026, 20:54 UTC

Winsten

Gap, Fortinet, and More Stocks That Usually Outperform After Earnings -- Barrons.com

12 jan 2026, 20:48 UTC

Marktinformatie

Oil Futures Settle Higher in Choppy Trade -- Market Talk

12 jan 2026, 20:33 UTC

Marktinformatie

U.S. Natural Gas Jumps on Colder Weather Outlook -- Market Talk

12 jan 2026, 20:18 UTC

Acquisities, Fusies, Overnames

Credit Agricole Sees Banco BPM Stake Helping 2025 Net by EUR200M >ACA.FR

12 jan 2026, 20:18 UTC

Acquisities, Fusies, Overnames

Credit Agricole: European Central Bank Approves Crossing of 20% Threshold in Share Capital of Banco BPM

12 jan 2026, 19:39 UTC

Marktinformatie

J&J CEO: Trump Pact Allows Company to Focus on Core Operations -- Market Talk

12 jan 2026, 19:36 UTC

Marktinformatie

Gold and Silver Set New Records on Fed Probe -- Market Talk

12 jan 2026, 19:36 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

12 jan 2026, 19:33 UTC

Marktinformatie

Venezuela's 'Proven' Oil Reserves Raises Questions -- Market Talk

12 jan 2026, 19:24 UTC

Acquisities, Fusies, Overnames

Dynavax: 'Party A' CEO Sent a Non-Binding $15/Shr Proposal on Dec. 23

12 jan 2026, 19:22 UTC

Acquisities, Fusies, Overnames

Dynavax Files Tender Offer Recommendation Statement Related to Sanofi Deal, Mentions Talks With 'Party A'

12 jan 2026, 18:21 UTC

Acquisities, Fusies, Overnames

Paramount Plans Proxy Fight to Push Hostile Warner Bid -- 2nd Update

12 jan 2026, 18:20 UTC

Acquisities, Fusies, Overnames

This French Biotech Stock Surged 1,700% in 2025. Eli Lilly Is Taking an Interest. -- Barrons.com

12 jan 2026, 18:19 UTC

Marktinformatie

Modest Canadian Economic Impact Seen from Venezuela Changes -- Market Talk

12 jan 2026, 18:16 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Comcast Could Unlock Value With a Spinoff of NBCUniversal Assets, Analysts Say -- Market Talk

12 jan 2026, 18:09 UTC

Marktinformatie

Global Equities Roundup: Market Talk

12 jan 2026, 18:09 UTC

Marktinformatie

Baidu's Outlook Bodes Well For Shares -- Market Talk

12 jan 2026, 18:01 UTC

Acquisities, Fusies, Overnames

QXO Is Raising Another $1.8 Billion for Its M&A War Chest -- Barrons.com

12 jan 2026, 18:00 UTC

Marktinformatie

Canada's 'Breakeven' Employment Recalibrating -- Market Talk

Peer Vergelijking

Prijswijziging

PerkinElmer Inc Prognose

Koersdoel

By TipRanks

11.47% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 113.38 USD  11.47%

Hoogste 123 USD

Laagste 105 USD

Gebaseerd op 10 Wall Street-analisten die 12-maands prijsdoelen bieden voor PerkinElmer Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

10 ratings

6

Buy

4

Hold

0

Sell

Sentiment

By Acuity

87 / 370 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over PerkinElmer Inc

Revvity, Inc. provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, BACS-on-Beads, BIOCHIPs, Bioo Scientific,BoBs , chemagic, Chitas, DELFIA, DELFIA Xpress, DOPlify, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, explorer, Fontus, Genoglyphix, GSP, Haoyuan, IDS, IDS-i10 IDS-i10T, IDS-iSYS, iLab, iQ, JANUS, LabChip, LifeCycle, LimsLink, Migele, MultiPROBE, NEXTFLEX, NextPrep, Pannoramic, Panthera Puncher, PG-Seq, PGFind PKamp, PreNAT II, Prime, Protein Clear, ProteinEXact, QSigh, QuantiVac, RONIA, Sciclone, SimplicityChrom, Specimen Gate,Superflex, Symbio, T-SPOT, Touch, Twister, Vanadis, VariSpec, ViaCord VICTOR 2D, and Zephyr brand name. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
help-icon Live chat